Cargando…
Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346538/ https://www.ncbi.nlm.nih.gov/pubmed/28348975 http://dx.doi.org/10.3389/fonc.2017.00031 |
| _version_ | 1782513895001292800 |
|---|---|
| author | Saba, Nabil F. |
| author_facet | Saba, Nabil F. |
| author_sort | Saba, Nabil F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5346538 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53465382017-03-27 Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) Saba, Nabil F. Front Oncol Oncology Frontiers Media S.A. 2017-03-13 /pmc/articles/PMC5346538/ /pubmed/28348975 http://dx.doi.org/10.3389/fonc.2017.00031 Text en Copyright © 2017 Saba. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Saba, Nabil F. Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title | Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title_full | Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title_fullStr | Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title_full_unstemmed | Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title_short | Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) |
| title_sort | commentary: randomized phase ii study of duligotuzumab (mehd7945a) vs. cetuximab in squamous cell carcinoma of the head and neck (mehgan study) |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346538/ https://www.ncbi.nlm.nih.gov/pubmed/28348975 http://dx.doi.org/10.3389/fonc.2017.00031 |
| work_keys_str_mv | AT sabanabilf commentaryrandomizedphaseiistudyofduligotuzumabmehd7945avscetuximabinsquamouscellcarcinomaoftheheadandneckmehganstudy |